Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Medical University of Vienna has been commissioned by international pharmaceutical firms to conduct three clinical trials of the treatment of recurrent prostate tumors (hormone refractory prostate carcinomas). The new approaches comprise immunotherapy, hormone therapy and an augmented form of the current standard treatment with Docetaxel.
Subscribe to our email newsletter
Reportedly, team leader Michael Krainer and his colleagues are expected to concentrate primarily on tumors diagnosed late or those which recur after surgical interventions, and which do not (or no longer) respond to common treatments such as androgen deprivation.
The Medical University of Vienna said that the team will investigate the use of the monoclonal antibody Ipilimumab as part of the immunotherapeutic treatment. The antibody can cause the body’s own immune system to react against cancer cells.
Prof Krainer said: “The use of Ipilimumab rather than Docetaxel has led to rather surprising successes during the past year in a small-scale trial. In three patients, a tumor that had been hard to treat became so small that it could be surgically removed. Since a small-scale trial of this nature only allows limited claims to be made about the drug, Ipilimumab is now being investigated further in a larger study.”
Additionally, a hormone treatment based on the drug MDV3100 is also being trialed by the team at the Medical University of Vienna. This is used as a second-line treatment after the initial treatment with Docetaxel. MDV3100 is a substance that blocks the androgen receptor and thus offers a new approach to the prevention of hormone dependent tumor growth.
In the past, Prof Krainer and his team were able to show the efficacy of Docetaxel versus other common chemotherapeutic drugs. The third trial at the Medical University of Vienna is expected to test the combination of Docetaxel with the tyrosine kinase inhibitor sunitinib. As part of the trial, the researchers will examine biomarkers in the patients’ blood that will yield information about the progress of the treatment.
Rene Siegl, managing director of the Austrian investment promotion company ABA – Invest in Austria, said: “We are delighted that multinational pharmaceutical companies find in Austria the optimal environment and competent partners for clinical trials and basic research. This shows that the conditions at the location Austria are ideal.”